Instytut Gruźlicy I Chorób Płuc Oddział Terenowy im. Jana i Ireny Rudników w Rabce Zdrój
- Address
- ul. Profesora Rudnika 3B, 34-700 Rabka Zdrój, Poland
Instytut Gruźlicy i Chorób Płuc - Rabka Zdrój Branch
The Jana and Irena Rudnik Institute of Tuberculosis and Lung Diseases, Rabka Zdrój Branch, is a specialized pulmonary research center dedicated to advancing treatment options for patients with chronic respiratory conditions. The facility focuses on evaluating innovative therapeutic approaches for complex pulmonary diseases, with particular emphasis on genetic and chronic lung disorders.
- Cystic fibrosis treatment development and clinical evaluation
- Inhalation therapy pharmacokinetics and safety assessment
- Novel drug delivery systems for respiratory conditions
The center has established expertise in conducting phase clinical trials evaluating the safety, tolerability, and preliminary efficacy of experimental medications. Their research capabilities include comprehensive dose-escalation studies and pharmacokinetic assessments, particularly for inhaled therapeutics targeting patients with cystic fibrosis and other chronic respiratory diseases requiring specialized long-term management.
Site Overview
Activity Indicator
Last 6 months
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Splisense Ltd.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Instytut Gruźlicy I Chorób Płuc Oddział Terenowy im. Jana i Ireny Rudników w Rabce Zdrój
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Cystic Fibrosis Patients with 3849+10 Kb C->T Mutation | Splisense Ltd. | Phase II | Not Yet Recruiting | Oct 2024 | — |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.